Matching articles for "Clear Eyes"
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Drugs for Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • April 19, 2021; (Issue 1622)
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table 1).
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • June 1, 2020; (Issue 1599)
A 0.24% ophthalmic solution of the second-generation
H1-antihistamine cetirizine (Zerviate – Eyevance) is now
available by prescription for treatment of ocular itching
associated with allergic...
A 0.24% ophthalmic solution of the second-generation
H1-antihistamine cetirizine (Zerviate – Eyevance) is now
available by prescription for treatment of ocular itching
associated with allergic conjunctivitis in patients ≥2
years old. Oral cetirizine (Zyrtec, and others), which is
used for treatment of allergic conjunctivitis and rhinitis,
has been available over the counter (OTC) for years.
OTC Brimonidine (Lumify) for Ocular Redness
The Medical Letter on Drugs and Therapeutics • October 22, 2018; (Issue 1558)
The FDA has approved an over-the-counter (OTC)
0.025% ophthalmic formulation of the selective
alpha2-adrenergic agonist brimonidine tartrate (Lumify
– Bausch & Lomb) for treatment of ocular redness...
The FDA has approved an over-the-counter (OTC)
0.025% ophthalmic formulation of the selective
alpha2-adrenergic agonist brimonidine tartrate (Lumify
– Bausch & Lomb) for treatment of ocular redness in
adults and children ≥5 years old. Lumify is the first
brimonidine product to be approved for OTC use.